GeoVax Labs, Inc.

Equities

GOVX

US3736786068

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2 USD +8.11% Intraday chart for GeoVax Labs, Inc. +3.63% -63.07%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress CI
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System CI
Transcript : GeoVax Labs, Inc., Q4 2023 Earnings Call, Feb 29, 2024
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GeoVax Labs Gets Two Patents from US Patent and Trademark Office MT
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster CI
Transcript : GeoVax Labs, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:30 PM
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology CI
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients CI
GeoVax Labs Files for 21.1 Million Share Offering by Selling Shareholder MT
Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02 CI
Transcript : GeoVax Labs, Inc., Q3 2023 Earnings Call, Nov 08, 2023
GeoVax Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine CI
GeoVax Labs Gets Notice of Allowance for US Patent Application Covering Marburg Vaccine MT
GeoVax Labs' HIV Vaccine Patent Gets Notice of Allowance from US Patent and Trademark Office MT
GeoVax Labs, Inc. Secures Multi-Product License for Probiogen's Age1.Cr.Pix(R) Suspension Cell Line to Bolster MVA-Based Vaccine Development CI
Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients CI
GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster CI
GeoVax Labs Says it Received Allowance Notice for Malaria Vaccine Patent Application MT
GeoVax Labs, Inc. Announces First Patients Vaccinated in Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia CI
Transcript : GeoVax Labs, Inc., Q2 2023 Earnings Call, Aug 09, 2023
GeoVax Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GeoVax Labs Starts Phase 2 Trial of COVID-19 Vaccine Booster in Chronic Lymphocytic Leukemia Patients MT
GeoVax Labs, Inc. Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia CI
Chart GeoVax Labs, Inc.
More charts
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.85 USD
Average target price
105 USD
Spread / Average Target
+5,575.67%
Consensus
  1. Stock
  2. Equities
  3. Stock GeoVax Labs, Inc. - Nasdaq
  4. News GeoVax Labs, Inc.
  5. MT Newswires After Hours Watch List: GOVX, LCID, LFMD